EichorEICHOR
Location: Las Palmas De Gran Canaria Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Las Palmas De Gran Canaria

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · Hospital Insular de Gran Canaria · Eli Lilly and Company · NCT07218380Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
Phase N/A · Hospital Materno Infantil de Gran Canaria · Spanish Oncology Genito-Urinary Group · NCT06724159Efficacy of the NXSignal Device for the Treatment of Anterior Cruciate Ligament Injuries
NA · University of Las Palmas de Gran Canaria · University of Las Palmas de Gran Canaria · NCT05207943Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)
Phase N/A · Hospital Materno Infantil de Gran Canaria · Biobizkaia Health Research Institute · NCT07240038A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · Hospital Insular de Gran Canaria · Eli Lilly and Company · NCT06119581A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Phase 2/Phase 3 · Hospital Universitario de Gran Canaria Doctor Negrin · Bluefin Biomedicine, Inc. · NCT07287644Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Hospital Universitario Insular de Gran Canaria ( Site 0867) · Merck Sharp & Dohme LLC · NCT03486873PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Phase 2 · Hospital Universitario de Gran Canaria Dr. Negrín · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT06409936A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Parti
Phase 3 · Hospital Insular de Gran Canaria-Oncology ( Site 2903) · Merck Sharp & Dohme LLC · NCT06312137Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Phase 3 · Hospital Universitario de Gran Canaria "" · Priothera SAS · NCT05429632A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resist
Phase 3 · Hospital Insular de Gran Canaria-Oncology ( Site 1280) · Merck Sharp & Dohme LLC · NCT06136650A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Pr
Phase 3 · H. Insular de Gran Canaria ( Site 2606) · Merck Sharp & Dohme LLC · NCT06717347IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Phase 3 · Hospital Universitario Insular De Gran Canaria · Immunocore Ltd · NCT06112314Hyperangulated vs Macintosh Blades for Intubation With Videolaryngoscopy in ICU
NA · Hospital Universitario de Gran Canaria Doctor Negrín · Hospital Clinico Universitario de Santiago · NCT06322719Spanish Registry of Patients With IgM Monoclonal Gammopathies
Phase N/A · Hospital Universitario de Gran Canaria Dr. Negrín · Fundación Española de Hematología y Hemoterapía · NCT05093153Computerized Registry of Patients With Venous Thromboembolism (RIETE)
Phase N/A · Complejo Hospitalario Universitario Insular Materno Infantil · Manuel Monreal · NCT02832245Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Phase 3 · Hospital Universitario de Gran Canaria Doctor Negrín · Bristol-Myers Squibb · NCT07116967A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Phase 3 · Hosp. U Gran Canaria Dr. Negrín_Cardiologia · Novo Nordisk A/S · NCT07567001Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Phase 2 · European Myeloma Network B.V. · NCT07107529Prevalence of Long COVID-19 in the Canary Islands
Phase N/A · University of Las Palmas de Gran Canaria · University of Las Palmas de Gran Canaria · NCT05228691Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Phase 3 · Hospital Universitario de Gran Canaria Doctor Negrín · Eli Lilly and Company · NCT07157774Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Phase 3 · Hospital Universitario de Gran Canaria Doctor Negrin · Amgen · NCT07037459EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes,
Phase 3 · Hospital de Gran Canaria Dr. Negrín · Boehringer Ingelheim · NCT07064473Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
Phase N/A · Complejo Hospitalario Universitario de Gran Canaria Dr. Negr · Spanish Breast Cancer Research Group · NCT03390894JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Phase 3 · Hospitales Universitarios San Roque En Las Palmas de Gran Ca · Johnson & Johnson Enterprise Innovation Inc. · NCT04892173Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Phase 3 · Universidad de Las Palmas de Gran Canaria · Summit Therapeutics · NCT05899608A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Ev
Phase 3 · Hospital Insular de Gran Canaria · Eli Lilly and Company · NCT07613294A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With
Phase 1/Phase 2 · Hospital Universitario Materno Infantil en las Palmas de Gra · Regeneron Pharmaceuticals · NCT05788536
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.